Press

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

May 11 • 5 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the first quarter 2023 and gave an update on recent progress across its business. “Our phase 3 pivotal trials in treatment-resistant depression are now underway and on track, with…

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

May 11 • 8 min read

atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported first quarter 2023 financial results and provided corporate updates. “We continue to focus on our vision to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. This past quarter we made significant…

Sunstone Therapies to present data on the long-term efficacy of psilocybin therapy in cancer patients with major depressive disorder (MDD) at the ASCO 2023 Annual Meeting

May 11 • 2 min read

Sunstone Therapies, a leader in the development of clinical trials and the delivery of psychedelic-assisted therapy in the medical setting, today announces that it will present data from the long-term study of psilocybin therapy in cancer patients with major depressive disorder (MDD). The data will be presented in a poster presentation at the American Society…

Mind Cure Closes Previously Announced Private Placement

May 11 • 1 min read

Mind Cure Health Inc. (OTCQB: MCURF / FRA: 6MH) is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement of units (each, a “Unit”) at $0.05 per Unit. The Company issued 2,500,000 Units for gross proceeds of $125,000. Each Unit consists of one common share and one-half of one share purchase warrant,…

Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants

May 11 • 1 min read

Clearmind Medicine Inc. (NASDAQ: CMND / CSE: CMND / FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has retained Crescendo Communications, LLC for strategic investor relations and capital markets communications services (the “Agreement”). In addition, the company announces the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435